Hondramín tablets, containing components derived from bovine cartilage, offer a complex of proteins and nucleoproteins selectively targeting cartilage cells. This promotes normalized chondrocyte metabolism and reduces the risk of various joint disorders. Clinical trials involving 120 patients with osteoarthritis of the knee, spinal osteochondrosis, and systemic osteoporosis demonstrated Hondramín's effectiveness. Assessment was based on subjective symptom improvement, objective laboratory and instrumental findings, and musculoskeletal function. The trials showed that Hondramín, as part of comprehensive therapy, significantly reduced pain and joint stiffness. The most notable effects were pain reduction and increased range of motion in affected joints. All patients experienced a substantial alleviation of typically therapy-resistant pathological symptoms. While clinical effects varied depending on disease stage (less pronounced in older patients), subjective feedback from this demographic remained highly positive. Hondramín is a dietary supplement – a source of polypeptides and nucleic acids – indicated for: degenerative-dystrophic joint and spinal diseases; post-joint and limb trauma; arthropathies of various etiologies; systemic connective tissue diseases; post-extreme physical exertion; pre- and postoperative periods following joint surgery; and systemic prevention of musculoskeletal disorders in elite athletes.
US: temporary delays — postal services aligning new import rules, 
EU: 1–2 weeks, 🌍 Worldwide: 1–4 weeks ✈️